Ambarella Inc vs GSK plc — how do they compare? Ambarella Inc trades at $84.08 (market cap $3.64B), while GSK plc trades at $50.58 (market cap $102.60B). The key difference: GSK plc is far larger — about 28.2× Ambarella Inc's market cap, and GSK plc pays a 3.57% dividend while Ambarella Inc pays none. Which is the better fit depends on your goals.
| AMBA | GSK | |
|---|---|---|
Market Cap | $3.64B | $102.60B |
Sector | Technology | Health |
52-Week High | $95.51 | $61.18 |
52-Week Low | $48.65 | $38.22 |
Enterprise Value | $3.37B | $123.04B |
Dividend Yield | — | 3.57% |
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $86.78, up 3.57% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics. Recent news highlights NXP's potential acquisition interest and the company's strategic pivot to edge AI chips, driving analyst optimism. Q2 2026 earnings are expected at $0.171 per share, following three consecutive quarterly beats. Revenue growth is projected to accelerate from $285M in 2025 to $405M in 2026.
Outlook remains positive with 58% analyst buy ratings and $108.67 price target, but risks include persistent net losses, high valuation multiples, and competitive pressure in semiconductor space. The edge AI transition offers growth potential, yet execution risks and insider selling warrant caution for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →